Evidence map›Paper›PMID 34169282›Full record

ArticleNeuro-oncology advances

Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients.

Elisa Izquierdo, Paula Proszek, Giulia Pericoli, Sara Temelso, Matthew Clarke, Diana M Carvalho, Alan Mackay, Lynley V Marshall, Fernando Carceller, Darren Hargrave and 13 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 2 pooled it
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. D-Loop Mutations as Prognostic Markers in Glioblastoma-A Pilot Study.International journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 11 institutions in 6 countries.

Elisa IzquierdoDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Paula ProszekMolecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, UK.
Giulia PericoliDepartment of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Sara TemelsoDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Matthew ClarkeDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Diana M CarvalhoDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Alan MackayDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Lynley V MarshallDivision of Clinical Studies, The Institute of Cancer Research, London, UK.
Fernando CarcellerDivision of Clinical Studies, The Institute of Cancer Research, London, UK.
Darren HargraveDepartment of Haematology and Oncology, UCL Great Ormond Street Institute for Child Health, London, UK.
Birgitta LanneringDepartment of Pediatrics, Institute of Clinical Sciences, Queen Silvia Children's Hospital, University of Gothenburg, Gothenburg, Sweden.
Zdenek PavelkaDepartment of Pediatric Oncology, University Hospital Brno - Children's Hospital, Brno, Czechia.
Simon BaileyDepartment of Paediatric Oncology, Great North Children's Hospital, Newcastle University Center for Cancer, Newcastle upon Tyne, UK.
Natacha Entz-WerlePediatric Onco-Hematology Department, University Hospital of Strasbourg, Strasbourg, France.
Jacques GrillPediatric and Adolescent Oncology and INSERM Unit U981, Team Genomics and Oncogenesis of Pediatric Brain Tumors, Gustave Roussy and Paris Saclay University, Villejuif, France.
Gilles VassalPediatric and Adolescent Oncology and INSERM Unit U981, Team Genomics and Oncogenesis of Pediatric Brain Tumors, Gustave Roussy and Paris Saclay University, Villejuif, France.
Daniel RodriguezMedical Physics and Clinical Engineering, Nottingham University Hospital Trust Nottingham University Hospital Trust, Nottingham, UK.
Paul S MorganMedical Physics and Clinical Engineering, Nottingham University Hospital Trust Nottingham University Hospital Trust, Nottingham, UK.
Tim JaspanDepartment of Radiology, Nottingham University Hospital Trust, Nottingham University Hospital Trust, Nottingham, UK.
Angela MastronuzziDepartment of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.ORCID https://orcid.org/0000-0002-4408-2373
Mara VinciDepartment of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy.
Michael HubankMolecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, UK.
Chris JonesDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
Institute of Cancer Research · GBNottingham University Hospitals NHS Trust · GBInserm · FRInstitute of Cancer Research · CARoyal Marsden Hospital · GBBambino Gesù Children's Hospital · ITCentre National de la Recherche Scientifique · FRGreat North Children's Hospital · GBGreat Ormond Street Hospital · GBUniversity Hospital Brno · CZUniversity of Gothenburg · SE

Funding

Cancer Research UK 23536
6 · The paper itself

Abstract

backgroundThe use of liquid biopsy is of potential high importance for children with high grade (HGG) and diffuse midline gliomas (DMG), particularly where surgical procedures are limited, and invasive biopsy sampling not without risk. To date, however, the evidence that detection of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) could provide useful information for these patients has been limited, or contradictory.

methodsWe optimized droplet digital PCR (ddPCR) assays for the detection of common somatic mutations observed in pediatric HGG/DMG, and applied them to liquid biopsies from plasma, serum, cerebrospinal fluid (CSF), and cystic fluid collected from 32 patients.

resultsAlthough detectable in all biomaterial types, ctDNA presented at significantly higher levels in CSF compared to plasma and/or serum. When applied to a cohort of 127 plasma specimens from 41 patients collected from 2011 to 2018 as part of a randomized clinical trial in pediatric non-brainstem HGG/DMG, ctDNA profiling by ddPCR was of limited use due to the small volumes (mean = 0.49 mL) available. In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in

conclusionTumor-specific DNA alterations are more readily detected in CSF than plasma. Although we demonstrate the potential of the approach to assessing tumor burden, our results highlight the necessity for adequate sample collection and approach to improve detection if plasma samples are to be used.

Indexed as

cfDNACSFctDNADIPGHGGplasma

Identifiers

PMID34169282
PMCPMC8218704
OpenAlexW3125975704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.